John P Houston

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex
    John P Houston
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46221, USA
    J Clin Psychiatry 67:1246-52. 2006
  2. pmc Symptoms predicting remission after divalproex augmentation with olanzapine in partially nonresponsive patients experiencing mixed bipolar I episode: a post-hoc analysis of a randomized controlled study
    John P Houston
    US Medical Neuroscience, Lilly USA, LLC Drop Code 4133, Indianapolis, IN 46285 USA
    BMC Res Notes 3:276. 2010
  3. doi request reprint Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study
    John P Houston
    Lilly USA, LLC, Drop Code 4133, Indianapolis, IN 46285, USA
    J Clin Psychiatry 70:1540-7. 2009
  4. doi request reprint Early symptom change and prediction of subsequent remission with olanzapine augmentation in divalproex-resistant bipolar mixed episodes
    John P Houston
    US Medical Neuroscience, Lilly USA, LLC, Drop Code 4133, Indianapolis, IN 46285, USA
    J Psychiatr Res 45:169-73. 2011
  5. doi request reprint Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women
    John Houston
    Lilly USA LLC, Indianapolis, IN, USA
    Psychiatry Res 187:74-9. 2011
  6. doi request reprint PDI-4A: an augmented provisional screening instrument assessing 5 additional common anxiety-related diagnoses in adult primary care patients
    John P Houston
    Lilly USA, LLC, Indianapolis, IN 46285, USA
    Postgrad Med 123:89-95. 2011
  7. ncbi request reprint Initial symptoms of manic relapse in manic or mixed-manic bipolar disorder: post hoc analysis of patients treated with olanzapine or lithium
    John P Houston
    Lilly Corporate Center, Lilly Research Laboratories, Drop Code 4133, Indianapolis, IN 46285, United States
    J Psychiatr Res 41:616-21. 2007
  8. doi request reprint Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia
    John P Houston
    Eli Lilly and Company, Indianapolis, Indiana, USA
    J Clin Psychiatry 73:1077-86. 2012
  9. doi request reprint Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients
    John P Houston
    Lilly USA, LLC, Indianapolis, IN 46285, USA
    Psychiatry Res 175:171-2. 2010
  10. doi request reprint Association of common variations in the norepinephrine transporter gene with response to olanzapine-fluoxetine combination versus continued-fluoxetine treatment in patients with treatment-resistant depression: a candidate gene analysis
    John P Houston
    Lilly USA, LLC, Indianapolis, IN 46285, USA
    J Clin Psychiatry 73:878-85. 2012

Detail Information

Publications32

  1. ncbi request reprint Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex
    John P Houston
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46221, USA
    J Clin Psychiatry 67:1246-52. 2006
    ..To identify symptoms associated with suicidality in bipolar I disorder patients, and to assess suicide risk during treatment with olan-zapine in combination with lithium or divalproex...
  2. pmc Symptoms predicting remission after divalproex augmentation with olanzapine in partially nonresponsive patients experiencing mixed bipolar I episode: a post-hoc analysis of a randomized controlled study
    John P Houston
    US Medical Neuroscience, Lilly USA, LLC Drop Code 4133, Indianapolis, IN 46285 USA
    BMC Res Notes 3:276. 2010
    ..At baseline, the two treatment groups were similar...
  3. doi request reprint Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study
    John P Houston
    Lilly USA, LLC, Drop Code 4133, Indianapolis, IN 46285, USA
    J Clin Psychiatry 70:1540-7. 2009
    ....
  4. doi request reprint Early symptom change and prediction of subsequent remission with olanzapine augmentation in divalproex-resistant bipolar mixed episodes
    John P Houston
    US Medical Neuroscience, Lilly USA, LLC, Drop Code 4133, Indianapolis, IN 46285, USA
    J Psychiatr Res 45:169-73. 2011
    ..Because remission with augmentation therapy may occur in as few as one in ten individuals who lack very early symptom reduction, lack of early improvement may indicate a need to expediently reassess treatment strategy...
  5. doi request reprint Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women
    John Houston
    Lilly USA LLC, Indianapolis, IN, USA
    Psychiatry Res 187:74-9. 2011
    ..Five of these SNPs fall in or are adjacent to an LD block spanning DRD2 intron 7, exon 7, 5' untranslated region and ANKK1. Clinical trial Registration: www.clinicaltrial.gov...
  6. doi request reprint PDI-4A: an augmented provisional screening instrument assessing 5 additional common anxiety-related diagnoses in adult primary care patients
    John P Houston
    Lilly USA, LLC, Indianapolis, IN 46285, USA
    Postgrad Med 123:89-95. 2011
    ..The PDI-4A may additionally help primary care physicians identify patients with PA, SP, OCD, hypochondriasis, and PTSD...
  7. ncbi request reprint Initial symptoms of manic relapse in manic or mixed-manic bipolar disorder: post hoc analysis of patients treated with olanzapine or lithium
    John P Houston
    Lilly Corporate Center, Lilly Research Laboratories, Drop Code 4133, Indianapolis, IN 46285, United States
    J Psychiatr Res 41:616-21. 2007
    ....
  8. doi request reprint Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia
    John P Houston
    Eli Lilly and Company, Indianapolis, Indiana, USA
    J Clin Psychiatry 73:1077-86. 2012
    ..We assessed the relationships between single-nucleotide polymorphisms (SNPs) in these genes with weight gain during treatment with olanzapine in a predominantly antipsychotic-naive population...
  9. doi request reprint Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients
    John P Houston
    Lilly USA, LLC, Indianapolis, IN 46285, USA
    Psychiatry Res 175:171-2. 2010
    ..In both cohorts, three dopamine receptor D2 (DRD2) SNPs were associated with prolactin changes. DRD2 may influence susceptibility to hyperprolactinemia associated with antipsychotic treatment...
  10. doi request reprint Association of common variations in the norepinephrine transporter gene with response to olanzapine-fluoxetine combination versus continued-fluoxetine treatment in patients with treatment-resistant depression: a candidate gene analysis
    John P Houston
    Lilly USA, LLC, Indianapolis, IN 46285, USA
    J Clin Psychiatry 73:878-85. 2012
    ..To determine whether single-nucleotide polymorphisms (SNPs) in candidate genes are associated with response to olanzapine-fluoxetine combination...
  11. doi request reprint Defining "good" and "poor" outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approach
    Ilya A Lipkovich
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Psychiatry Res 170:161-7. 2009
    ..Early symptom response significantly improved the prediction of outcome, suggesting that early monitoring of treatment response may be useful in clinical practice...
  12. doi request reprint Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression
    Eileen Brown
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Int J Neuropsychopharmacol 12:773-82. 2009
    ..There was no treatment difference in incidence of relapse. OFC-treated patients had more treatment-emergent adverse events and greater incidence of weight gain and hypercholesterolaemia...
  13. doi request reprint The association of single nucleotide polymorphisms in the catechol-O-methyltransferase gene and pain scores in female patients with major depressive disorder
    Bonnie Fijal
    Eli Lilly and Company Lilly Corporate Center, Indianapolis, Indiana, USA
    J Pain 11:910-5, 915.e1-9. 2010
    ..This finding could potentially help clinicians who seek to assess how genetic polymorphisms may contribute to a patient's pain experience...
  14. doi request reprint A provisional screening instrument for four common mental disorders in adult primary care patients
    John P Houston
    Lilly USA, LLC, Indianapolis, IN 46285, USA
    Psychosomatics 52:48-55. 2011
    ..To develop an adult self-report instrument for provisional diagnosis of four common mental disorders in primary care patients...
  15. doi request reprint Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder
    David H Adams
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Hum Psychopharmacol 23:267-74. 2008
    ..To test association of dopamine receptor D3 (DRD-3) gene polymorphisms with olanzapine response in genetic samples from a registration phase clinical trial...
  16. doi request reprint Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone
    Bonnie A Fijal
    Lilly USA, Indianapolis, IN 46285, USA
    J Clin Psychiatry 73:367-71. 2012
    ..We examined 6 single nucleotide polymorphisms (SNPs) previously reported to be associated with response to iloperidone therapy for association with response to risperidone therapy...
  17. pmc Evaluating dose response from flexible dose clinical trials
    Ilya Lipkovich
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis Indiana, USA
    BMC Psychiatry 8:3. 2008
    ..The true dose effect in flexible-dose clinical trials may be obscured and even reversed because dose and outcome are related...
  18. pmc A cross-validation of the provisional diagnostic instrument (PDI-4)
    Douglas E Faries
    Lilly Research Laboratories, Indianapolis, IN, USA
    BMC Fam Pract 13:104. 2012
    ..Our objective was to assess validity of the PDI-4 in a population independent of the study population originally used to develop the scale...
  19. doi request reprint Association of catechol-O-methyltransferase variants with duloxetine response in major depressive disorder
    John P Houston
    Neuroscience Department, Eli Lilly and Company, LLC, Indianapolis, IN, USA
    Psychiatry Res 189:475-7. 2011
    ..COMT rs165737 and a diplotype containing COMT rs165599 and COMT rs165737 were associated with HAMD(17) total score changes...
  20. doi request reprint Evaluation of genetic models for response in a randomized clinical trial of duloxetine in major depressive disorder
    John P Houston
    Lilly USA, LLC, US Medical Neuroscience Department, Indianapolis, IN 46285, USA
    Psychiatry Res 200:63-5. 2012
    ..020) of a composite risk score (based on SLC6A2 rs5569 [G1287A] AA, HTR1A rs6295 [C(-1019)G] GG, and COMT rs174697 AA/AG) with 17-item Hamilton Depression Rating Scale total score change from baseline to 12 weeks was observed...
  21. ncbi request reprint Early predictors of substantial weight gain in bipolar patients treated with olanzapine
    Ilya Lipkovich
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:316-20. 2006
    ..Patients with less pronounced early weight gain might still be at risk for later SWG if they have close to normal BMI (< or =27 kg/m) at treatment initiation...
  22. pmc Identifying patterns in treatment response profiles in acute bipolar mania: a cluster analysis approach
    Ilya A Lipkovich
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46221, USA
    BMC Psychiatry 8:65. 2008
    ..The objective of this exploratory analysis was to characterize response in bipolar disorder by identifying groups of patients with similar manic symptom response profiles...
  23. ncbi request reprint Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram)
    Craig H Mallinckrodt
    Lilly Research Laboratories, Indianapolis, Ind 46285, USA
    Neuropsychobiology 56:73-85. 2007
    ....
  24. ncbi request reprint Characteristics and mortality among hospitalized patients treated with intramuscular antipsychotics: analysis of a United States hospital database
    Karen C Holdridge
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Curr Drug Saf 5:203-11. 2010
    ..73, 95% CI 0.57-0.93; p=.011). The results suggest that patients treated with IM olanzapine do not have a significantly greater risk of death than patients treated with IM haloperidol or IM ziprasidone...
  25. ncbi request reprint Neuroreceptor gene polymorphisms and olanzapine depressive symptom response in schizophrenia
    John P Houston
    J Clin Psychopharmacol 27:520-3. 2007
  26. ncbi request reprint A multivantaged behavioural method for measuring onset and sequence of the clinical actions of antidepressants
    Martin M Katz
    Department of Psychiatry, University of Texas Health Science Center, San Antonio, TX, USA
    Int J Neuropsychopharmacol 7:471-9. 2004
    ..Thus, the Brief MV, in uncovering underlying behavioural actions, represents an important addition to the current unidimensional HAMD approach in drug research...
  27. ncbi request reprint A video method for the evaluation of antidepressant clinical and behavioural actions
    Martin M Katz
    Department of Psychiatry, University of Texas Health Science Center, San Antonio, TX, USA
    Int J Neuropsychopharmacol 9:327-36. 2006
    ..e. effect motor activity and depressed mood, and paroxetine to reduce global severity and anxiety. The study shows the VIBES to be capable of uncovering behavioural mechanisms underlying AD's capacity to resolve depressive disorder...
  28. ncbi request reprint A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia
    John Battaglia
    Program of Assertive Community Treatment, Madison, WI 53703, USA
    Clin Ther 27:1612-8. 2005
    ..Acutely agitated patients with schizophrenia might require treatment with IM antipsychotics, followed by a transition to oral medication...
  29. ncbi request reprint Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodes
    Terence A Ketter
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA
    J Clin Psychiatry 67:95-101. 2006
    ..We investigated treatment efficacy in prevention of mood episodes in patients subgrouped by number of prior manic episodes...
  30. ncbi request reprint Association of acute symptoms and compliance attitude in noncompliant patients with schizophrenia
    Hong Liu-Seifert
    J Clin Psychopharmacol 27:392-4. 2007
  31. ncbi request reprint An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder
    Franca Centorrino
    McLean Hospital, Harvard Medical School, Boston, MA, USA
    Hum Psychopharmacol 22:455-62. 2007
    ..To determine the effect of intramuscular (IM) olanzapine in severely agitated patients...
  32. ncbi request reprint Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression
    Martin M Katz
    Department of Psychiatry, The University of Texas Health Science Center, San Antonio, TX, USA
    Neuropsychopharmacology 29:566-79. 2004
    ..Early drug-specific behavioral changes were highly predictive of ultimate clinical response to the different ADs, results that could eventually be applied directly to clinical practice...